Intelligence Profile
Research Papers
Research Papers on FOXO4-DRI
The research on FOXO4-DRI (FOXO4-D-Retro-Inverso) is primarily in preclinical stages, with no clinical trials currently available in the literature. The compound is being investigated as a senolytic agent—a therapy designed to selectively eliminate senescent cells that accumulate with aging and contribute to various diseases.
Mechanism of Action Studies
The foundational research establishes that FOXO4-DRI works by targeting the interaction between FOXO4 and p53 proteins. A 2025 Nature Communications study (PMID: 40593617) identified that the compound specifically targets the disordered p53 transactivation domain, disrupting the FOXO4-p53 interaction that normally keeps senescent cells alive. This mechanism was further validated in endothelial cells, where FOXO4-DRI was shown to regulate senescence through the p53 signaling pathway (Frontiers in Bioengineering and Biotechnology, 2025).
Disease Applications in Preclinical Models
Research has explored FOXO4-DRI's therapeutic potential across several conditions:
Fibrotic Diseases: A 2023 study in mice demonstrated that FOXO4-DRI reduced extracellular matrix production in fibroblasts and improved bleomycin-induced pulmonary fibrosis, suggesting potential for treating lung scarring conditions.
Dermatological Applications: Research published in Communications Biology (2025) showed that FOXO4-DRI induced apoptosis in keloid senescent fibroblasts by promoting nuclear exclusion of phosphorylated p53, indicating possible applications for treating keloid scars.
Age-Related Fertility: A 2024 study in aged mice found that FOXO4-DRI improved spermatogenesis by reducing harmful secretions from aged Leydig cells, suggesting potential benefits for age-related male fertility decline.
Neurological Applications: A 2026 study explored FOXO4-DRI and related retro-inverso peptides as potential treatments for brain aging and cognitive decline, though specific study details and sample sizes were not provided in the available abstracts.
Limitations of Current Evidence
The research remains entirely preclinical, conducted primarily in cell cultures and animal models. Sample sizes, specific dosing regimens, and detailed safety profiles are not consistently reported in the available literature. No human clinical trials have been conducted to date, representing a significant gap in translating these promising preclinical findings to clinical practice.
This information is for educational purposes only and should not be considered medical advice. Consult healthcare professionals for medical guidance.